Hung-Wei Wang

9PUBLICATIONS
26CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Apr 20, 2026
Absence of steatosis combined with cardiometabolic risk factors confers the highest hepatocellular carcinoma risk in treated chronic hepatitis B.

|Nov 18, 2024
Real-world experience of lenvatinib-based therapy in patients with advanced hepatocellular carcinoma.

Hung-Wei Wang, Hsueh-Chou Lai, Wen-Pang Su

|Aug 28, 2024
Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab.

Ying-Chun Shen, Tsung-Hao Liu, Alan Nicholas

|Dec 22, 2023
Adjuvant Sorafenib for Postoperative Patients with Hepatocellular Carcinoma and Macrovascular Invasion.

Che-Jui Chang, Wei-Fan Hsu, Long-Bin Jeng

|Oct 27, 2022
Modified Albumin-Bilirubin Model for Stratifying Survival in Patients with Hepatocellular Carcinoma Receiving Anticancer Therapy.

Wei-Fan Hsu, Shih-Chao Hsu, Te-Hong Chen

|Jun 03, 2022
Posttreatment nonalcoholic fatty liver disease fibrosis scores for predicting liver-related complications in patients with chronic hepatitis C receiving direct-acting antiviral agents.

Wei-Fan Hsu, Hsueh-Chou Lai, Po-Heng Chuang

Pageof 2

Frequent Collaborators

7 joint publications

Cheng-Yuan Peng

5 joint publications

Wei-Fan Hsu

3 joint publications

Hsueh-Chou Lai

1 joint publications

Ying-Chun Lin